Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals

Y.E. Thomassen, A.G. van 't Oever, M.G.C.T. van Oijen, R.H. Wijffels, L.A. van der Pol, W.A.M. Bakker

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)

Abstract

Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore, development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be transferred worldwide to support post polio-eradication biosafety goals.
Original languageEnglish
Article numbere83374
JournalPLoS ONE
Volume8
Issue number12
DOIs
Publication statusPublished - 2013

Keywords

  • sabin strains
  • technology-transfer
  • antigen
  • ipv
  • immunogenicity
  • culture
  • growth
  • safety
  • trial
  • cells

Fingerprint

Dive into the research topics of 'Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals'. Together they form a unique fingerprint.

Cite this